Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy is an X-linked neuromuscular disorder caused by pathogenic DMD variants leading to progressive muscle degeneration from early childhood.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Duchenne Muscular Dystrophy (DMD) in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| AAV Antibodies |
|
Defined at the solid tumor level and applicable to Duchenne Muscular Dystrophy (DMD) and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Duchenne Muscular Dystrophy (DMD). Select a therapy to view the specific approval and eligible tests.
AAV Antibodies (serotype rh74)